13863
post-template-default,single,single-post,postid-13863,single-format-standard,strata-core-1.0.1,strata-child-theme-ver-1.0.0,strata-theme-ver-3.0.3,ajax_fade,page_not_loaded,wpb-js-composer js-comp-ver-6.0.3,vc_responsive

Antibody testing for COVID-19 starts at Rutherford Cancer Centre

14:37 20 April in Berkshire, Life Sciences & Healthcare, News, Talent and Innovation

Reading based Rutherford Health plc has started coronavirus antibody testing for its staff and patients. Tests are being carried out in Rutherford Centres across the UK including Newport, Bedlington, Northumberland and Liverpool, before being processed at a laboratory in Middlesex. Data is being provided to Government ministers and advisers on testing.  

“It is vital that patients are as safe as possible when they are being treated and testing will help enormously. It is also hugely important that medical and nursing staff know their status as they are mixing with patients on a daily basis. Our patients include those referred by the NHS and we are engaging in dialogue with the government over the data from our testing.”

Professor Karol Sikora, Chief Medical Officer, Rutherford Health 

 

“We were ale secure testing kits from South Korea which had been used successful in Germany. Our primary concern is ensuring the safety of patients and staff.”

Mike Moran, Chief Executive, Rutherford Heath

 

Opening its doors in 2018 The Rutherford Cancer Centre meets growing demand for advanced cancer care and its proton beam therapy suite (opened in 2019) was the first of its calibre in the South East. The centre plays a crucial role in progressing medication throughout the region and provide patients with a wide range of therapies.  

The centre was established in Reading due to thriving healthcare and biotech scene, as well as its excellent location for patients to travel from Heathrow or other UK travel hubs.   

Read more, HERE